Dolphin Entertainment Bolsa (NASDAQ: DLPN)

Dolphin Entertainment (NASDAQ:DLPN) Bolsa

Dolphin Entertainment

Dolphin Entertainment Inc is an independent entertainment marketing and production company. It provides strategic marketing and publicity services to many of the top brands, both individual and corporate, in the motion picture, television, music, gaming, culinary, hospitality, and lifestyle industries. It operates in two reportable segments: Entertainment publicity and marketing and Content production. It generates the majority of its revenue from the Entertainment publicity and marketing segment which provides clients with diversified marketing services, including public relations, entertainment and hospitality content marketing, strategic marketing consulting, and content production of marketing materials.

Dolphin Entertainment, Inc. - Common Stock

Dolphin Entertainment Inc

Preclinical data demonstrate potent single-agent and combination effects in head and neck squamous cell carcinoma (HNSCC) models, including synergy with anti–PD-1 therapy
Initial Phase 1 clinical update shows early disease control in first HPV+ patient treated with APR-1051
DOYLESTOWN, Pa., June 25, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APRE#NASDAQ">APRE</a>) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities&nbsp;while minimizing damage to healthy cells, today announced new preclinical data and a clinical update on APR-1051, the Company's next-generation oral WEE1 inhibitor, in human papillomavirus–positive (HPV+) head and neck squamous cell carcinoma (HNSCC).
These findings result from an ongoing translational research collaboration with renowned oncology leader MD Anderson Cancer Center and support the potential of APR-1051 both as a single agent and in rational immunotherapy combinations for biomarker-driven treatment of HPV+ HNSCC. "We are excited by the preclinical data generated by independent researchers, and the early clinical signal of APR-1051 in an HPV-positive cancer patient," said Oren Gilad, Ph.D., President and Chief Executive Officer of Aprea Therapeutics. "We believe that APR-1051 could offer significant differentiation in the competitive oncology landscape, as a single agent, as well as in combination with checkpoint inhibitors."

Biotech

News

General

APRE

Aprea Therapeutics Presents APR-1051 Preclinical And Early Clinical Results In HPV+ Head And Neck Cancer

VEEV

Veeva Expands AWS Relationship

LiqTech International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIQT#NASDAQ">LIQT</a>), a leading clean technology company that manufactures and markets highly specialized filtration technologies, today announced it has received an order for the delivery of an advanced membrane-based filtration system to treat oily wastewater from North Star BlueScope Steel, a major U.S.-based steel producer.
The system, designed to resolve recurring filtration process upsets caused by high oil content and variability in wastewater quality, is scheduled to be commissioned and begin operation in the second half of calendar year 2025.
The wastewater filtration solution uses LiqTech's robust Silicon Carbide (SiC) membrane technology designed to withstand harsh industrial water conditions and deliver consistent, high-quality filtration. This ceramic ultrafiltration system will serve as a critical pre-treatment step to a downstream reverse osmosis system, enhancing overall process stability and water recovery efficiency.
While crossflow filtration is the most sustainable wastewater treatment process, it comes with a major volume-in to volume-out challenge. LiqTech's ceramics-based system addresses this challenge while adapting to ever-changing oil and turbid water quality.
Fei Chen, CEO of LiqTech, commented: "We are proud to support North Star BlueScope Steel with our proven solution to a complex challenge. This project demonstrates our growing traction in industrial water treatment and our ability to contribute meaningfully to our customers' operational efficiency and sustainability goals."
Tony Grant, Services Senior Mechanic, North Star BlueScope Steel, added: "North Star's proximity to the Great Lakes keeps responsible water use top-of-mind for our entire team. We are excited to see how LiqTech's technology will further enable our water preservation efforts through enhancements to our water recovery technology."
The addition of advanced wastewater pre-treatment filtration supports North Star's broader water reclamation initiatives and reflects a growing trend in the steel industry toward more sustainable water management practices.

Contracts

LIQT

Liqtech Internationa Announces It Has Received An Order For Delivery Of An Advanced Membrane-Based Filtration System To Treat Oily Wastewater From North Star Bluescope Steel

Canalevia&#xAE; (crofelemer delayed-release tablets), under the name Canalevia-CA1, is conditionally approved by the FDA for treatment of chemotherapy-induced diarrhea in dogs
Jaguar is exploring the possibility of approval of Canalevia for treatment of general diarrhea in dogs in the EU based on the statistically significant data from a completed study
Diarrhea is one of the most common reasons owners bring their dog to the veterinarian and the second most common reason for visits to the veterinary emergency hospital, yet there are currently no FDA-approved drugs to treat general diarrhea in dogs
Company strategy: In discussions with multiple potential animal health company partners to collaborate to bring Canalevia to regulatory approval and commercialization for general diarrhea globally
SAN FRANCISCO, CA / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / June 25, 2025 / <a href="https://pr.report/bt7v">Jaguar Health, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) (Jaguar), under its Jaguar Animal Health tradename for the veterinary market, today announced that the company plans to pursue approval from the European Medicines Agency's (EMA) <a href="https://pr.report/bt7x">Committee for Veterinary Medicinal Products</a> (CVMP) for Canalevia (crofelemer delayed-release tablets) in the European Union for treatment of general diarrhea in dogs. Canalevia, under the name <a href="https://pr.report/bt7y">Canalevia-CA1</a>, is conditionally approved by the U.S. Food and Drug Administration (FDA) as a prescription drug for the treatment of chemotherapy-induced diarrhea (CID) in dogs.

JAGX

Jaguar Health Pursues EU Approval For Canalevia To Treat General Dog Diarrhea

Bitcoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) transformation from a speculative digital experiment into a sophisticated macroeconomic asset is reshaping the crypto and financial markets alike, according to a new Glassnode report.
What Happened: In a <a href="https://get.glassnode.com/bitcoin-liquidity-trends-report-2025/">joint report</a>, Glassnode and Avenir Group outline how Bitcoin's growing institutional maturity, structural liquidity and macro alignment position it as a serious contender on the global stage.
Bitcoin&#8217;s Institutional Maturation
<ul class="wp-block-list">
<li>Institutional adoption has reached unprecedented levels, thanks to catalysts like the U.S. spot Bitcoin ETFs, dubbed by analysts as "the most successful ETF launch in history."</li>
<li>Since November 2022, Bitcoin has absorbed over $544 billion in new capital, propelling internal liquidity to a record $944 billion, just shy of the $1 trillion milestone.</li>
<li>This marks a defining shift from retail-driven cycles to one dominated by institutional capital and macro forces.</li>
</ul>
Bitcoin's historical performance has shown a stark similarity to current levels.
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>2015-2018 Current Performance</td>
<td>+1,059%</td>
</tr>
<tr>
<td>2018-2022 Current Performance</td>
<td>+1,007%</td>
</tr>
<tr>
<td>2022+ Current Performance</td>
<td>+656%</td>
</tr>
</tbody>
</table>
</figure>
Market Infrastructure Deepens
<ul class="wp-block-list">
<li>Centralized exchanges now support billions in daily BTC volume, with peak inflows/outflows reaching $11.3 billion in a single day during the 2022 cycle.</li>
<li>Derivatives markets are thriving, total futures and options open interest ballooned from $11.1 billion (December 2022) to $114 billion during Bitcoin's recent $100,000 breakout.</li>
<li>Advanced analytics like order book imbalances and cumulative volume delta (CVD) are now integral, signaling a highly sophisticated market microstructure.</li>
</ul>
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46089127/arthur-hayes-doubles-down-on-250000-bitcoin-call-sees-1-million-by-2028">Arthur Hayes Doubles Down On $250,000 Bitcoin Call — Sees $1 Million By 2028</a>
Among other contributing factors responsible for Bitcoin's shaping,
Macro Integration Strengthens
<ul class="wp-block-list">
<li>Bitcoin's correlation with major financial indices like the (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NASDAQ">SPY</a>), (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), gold and the global liquidity Index is rising, showing it trades like a true risk asset.</li>
<li>In contrast, Bitcoin's negative correlation with defensive assets like the dollar index and junk bond spreads indicates its role in expansionary cycles.</li>
<li>This reflects a new identity for Bitcoin, no longer just a speculative bet, but a leveraged play on global liquidity.</li>
</ul>
Altcoin Divergence Emerges
<ul class="wp-block-list">
<li>Despite strong crypto market growth, only Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>) and XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>) have outperformed Bitcoin among large-cap coins since January 2023.</li>
<li>Ethereum's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) dominance has waned in the current cycle, as liquidity spreads more broadly and BTC captures the bulk of institutional flows.</li>
<li>Bitcoin's market cap has grown 728% this cycle, compared to 500% for altcoins, highlighting BTC&#8217;s outperformance.</li>
</ul>
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Change From</td>
<td>Change To</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>$170.7 billion</td>
<td>$67.6 billion</td>
</tr>
<tr>
<td>Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>$33.9 billion</td>
<td>$54.9 billion</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$25.7 billion</td>
<td>$11.4 billion</td>
</tr>
<tr>
<td>XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>$15.3 billion</td>
<td>$38.6 billion</td>
</tr>
<tr>
<td>BNB (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/bnb/usd">BNB</a>)</td>
<td>$11.8 billion</td>
<td>$31.1 billion</td>
</tr>
<tr>
<td>Tron (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/trx/usd">TRX</a>)</td>
<td>$3.3 billion</td>
<td>$9.9 billion</td>
</tr>
<tr>
<td>Toncoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">TON</a>)</td>
<td>$500 million</td>
<td>$4.6 billion</td>
</tr>
</tbody>
</table>
</figure>
With scale, regulatory clarity, and macro alignment, Bitcoin is now positioned more like gold or equities than a typical crypto token, the report concludes.
It's not just a digital asset anymore, it&#8217;s becoming a cornerstone of macro portfolios, attracting deep institutional capital and setting itself apart from the rest of the crypto landscape.
Read Next: &nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46081761/bitcoin-dominance-tops-65-but-altcoin-season-is-close-trader-says">Bitcoin Dominance Tops 65% But &#8216;Altcoin Season&#8217; Is Close, Trader Says</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BNB

$BTC

$DOGE

$ETH

$SOL

$TON

$TRX

$XRP

How Bitcoin Is Maturing To A Global Liquidity Asset: Report

Barclays analyst Julien Roch downgrades WPP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WPP#NYSE">WPP</a>) from Equal-Weight to Underweight.

Downgrades

Analyst Ratings

Barclays Downgrades WPP to Underweight

INVO Fertility, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVF#NASDAQ">IVF</a>) ("INVO Fertility" or the "Company"), a healthcare company focused on the fertility sector, today announced it has received a notice of allowance on a new patent for a modified version of the Company's proprietary INVOcell device. The new patent extends intellectual property protection on the Company's INVOcell device through 2040 based on a modified design which reflects feedback from leading embryologists to simplify use of the device.
The United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 16/949,960, titled "Intravaginal Culture Incubation Container and Method." The Notice of Allowance, dated June 17, 2025, indicates that the USPTO has completed its examination and found the claims patentable. Once the issue fee is paid, the patent will be granted and published, providing protection to the claimed invention for 20 years from the filing date.
INVOcell is the world's first FDA-cleared intravaginal culture (IVC) system, a patented medical device that enables fertilization and early embryo development to occur within a woman's body, offering a more natural and intimate alternative to traditional in vitro fertilization (IVF). During the INVOcell procedure, eggs and sperm are placed in the thumb-sized device, which is then inserted into the vaginal cavity, typically, for a 5-day incubation period, utilizing the body's natural environment as an incubator. After incubation, embryos are transferred to the uterus, with any remaining embryos available for freezing. This innovative approach delivers comparable pregnancy rates to IVF—as reflected in the Company's 510k submission that was cleared by the FDA in 2023.
INVOcell was originally granted FDA clearance in 2015 and, in 2023, received clearance from the FDA for a change in labeling that increased the incubation period from 3 days to 5 days. The original INVOcell device included both a main chamber and microchamber. As real-world use cases of INVOcell have occurred over the past number of years, feedback from embryologists highlighted a preference for a singular main chamber without a separate microchamber. The Company redesigned the INVOcell device to reflect the feedback and subsequently submitted a modified device design for patent.
"The INVOcell device has represented a unique and alternative fertility treatment option, offering a more patient-centered approach that empowers couples by allowing fertilization and early embryo development to occur within the woman's body," commented Steve Shum, CEO of INVO Fertility. "The receipt of a new patent for our simplified device expands our intellectual property protection to this innovative approach, which delivers success rates comparable to traditional IVF, helping to make parenthood more accessible and inclusive for those facing infertility challenges worldwide."

INVO Fertility Announces It Received Notice Of Allowance For Modified INVOcell Device Patent

WIIM

INDP

Indaptus Therapeutics shares are trading lower after the company announced it will effect a reverse stock split at a ratio in the range of 1-for-5 and 1-for-28.

RBNE

Robin Energy shares are trading lower after the company announced the pricing of a 1,020,000 share registered direct offering at $3.50 per share.

XTIA

XTI Aerospace shares are trading lower after the company announced the pricing of a $16 million offering of 9,143,000 shares and 9,143,000 warrants at $1.75 per share and Common Warrant.

Management

ULTA

Ulta Beauty Appoints Chris Lialios Interim CFO

Robin Energy Ltd. Announces Pricing Of 1,020,000 Share Registered Direct Offering At Price Of $3.50

Barclays analyst Julien Roch downgrades Omnicom Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMC#NYSE">OMC</a>) from Overweight to Equal-Weight and lowers the price target from $105 to $80.

Price Target

Barclays Downgrades Omnicom Group to Equal-Weight, Lowers Price Target to $80

First Citizens BancShares's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCNCA#NYSE">FCNCA</a>) short percent of float has risen 12.03% since its last report. The company recently reported that it has 448 thousand shares sold short, which is 4.75% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.74 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>First Citizens BancShares Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750856434_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for First Citizens BancShares has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing First Citizens BancShares's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, First Citizens BancShares's peer group average for short interest as a percentage of float is 1.70%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

FCNCA

Is First Citizens BancShares Gaining or Losing Market Support?

WEC Energy Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WEC#NYSE">WEC</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $108.25, along with a high estimate of $124.00 and a low estimate of $100.00. This current average has increased by 1.64% from the previous average price target of $106.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1750856433_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The analysis of recent analyst actions sheds light on the perception of WEC Energy Group by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carly Davenport</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Sell</td>
<td>$100.00</td>
<td>$106.00</td>
</tr>
<tr>
<td>Neil Kalton</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$124.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Nicholas Campanella</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$101.00</td>
<td>$99.00</td>
</tr>
<tr>
<td>Jeremy Tonet</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$108.00</td>
<td>$106.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to WEC Energy Group. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of WEC Energy Group compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of WEC Energy Group's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of WEC Energy Group's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/WEC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on WEC Energy Group analyst ratings.</a>
<h2>Unveiling the Story Behind WEC Energy Group</h2>
WEC Energy Group's electric and gas utility businesses serve electric and gas customers in Illinois, Michigan, Minnesota, and Wisconsin service territories. The company also owns a 60% stake in American Transmission Co. WEC's asset mix is approximately 49% electric generation and distribution, 34% gas distribution, 10% electric transmission, and 7% unregulated renewable energy.
<h3>WEC Energy Group: Delving into Financials</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: WEC Energy Group's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 17.51%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Utilities sector.
Net Margin: WEC Energy Group's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 22.99%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): WEC Energy Group's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 5.71%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): WEC Energy Group's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.52%, the company showcases efficient use of assets and strong financial health.
Debt Management: WEC Energy Group's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.58.
<h2>The Basics of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing WEC Energy Group: Insights From 4 Financial Analysts

Energy Transfer's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ET#NYSE">ET</a>) short percent of float has fallen 6.06% since its last report. The company recently reported that it has 28.67 million shares sold short, which is 0.93% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.96 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Energy Transfer Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750856429_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Energy Transfer has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Energy Transfer's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Energy Transfer's peer group average for short interest as a percentage of float is 3.66%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Is the Market Bullish or Bearish on Energy Transfer?

Keysight Techs's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEYS#NYSE">KEYS</a>) short percent of float has fallen 4.57% since its last report. The company recently reported that it has 2.24 million shares sold short, which is 1.67% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.68 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Keysight Techs Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750856424_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Keysight Techs has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Keysight Techs's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Keysight Techs's peer group average for short interest as a percentage of float is 8.15%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

KEYS

What's Driving the Market Sentiment Around Keysight Techs?

As U.S. Treasuries wobble under the weight of budget deficits and rate uncertainty, <a href="https://in.benzinga.com/markets/emerging-markets">emerging market debt</a> is quietly staging a comeback — offering higher real yields, currency resilience, and inflation breathing room.
Investors accustomed to reflexively retreating to Treasuries in times of volatility are reconsidering. The iShares 20+ Year Treasury Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>) is down over 8% over the past year, and still negative year-to-date.
In contrast, EM debt ETFs are showing strength: the iShares JP Morgan EM Local Currency Bond ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEMB#NYSE">LEMB</a>) is up nearly 10% year-to-date, while the VanEck JP Morgan EM Local Currency Bond ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMLC#NYSE">EMLC</a>) and the SPDR Bloomberg Emerging Markets Local Bond ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBND#NYSE">EBND</a>) have returned over 7%.
Even more compelling? These gains come as local inflation trends across emerging markets soften, not heating up.
Read Also: <a href="https://www.benzinga.com/etfs/specialty-etfs/25/06/46064634/vanguard-slashes-fees-across-european-fixed-income-ucits-etfs-enhancing-low-cost-investing-options">Vanguard Slashes Fees Across European Fixed Income UCITS ETFs, Enhancing Low-Cost Investing Options</a>
<h3 class="wp-block-heading">Real Yield Advantage Is Back</h3>
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="611" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24065955/image-355-1024x611.png" alt="" class="wp-image-959609" style="width:736px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24065955/image-355-1024x611.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24065955/image-355-300x179.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24065955/image-355-768x458.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24065955/image-355-1536x916.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24065955/image-355.png 1979w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
The numbers tell the story:
<ul class="wp-block-list">
<li>Brazil&#8217;s 10-year government bond yields sit at a jaw-dropping 13.84%, while inflation has cooled to 5.32% &#8211; still above target but declining. That's a real yield north of 8%. </li>
<li>India's 10-year yield is 6.36% with inflation just 2.82%.</li>
<li>Indonesia yields 6.76% against inflation of 1.6%.</li>
</ul>
Compare that with the U.S., where 10-year yields are 4.35% and inflation ticked up to 2.4% in May, after four straight months of decline. While still moderate, the uptick &#8211; driven by food and transportation &#8211; suggests limited near-term relief for real yields. Core inflation held steady at 2.8%, reinforcing the Fed's cautious stance.
In short, emerging markets are offering stronger inflation-adjusted returns, with less policy ambiguity.
<h2 class="wp-block-heading">Currency Strength Adds Another Layer</h2>
For years, dollar dominance made EM debt vulnerable. Not anymore. 
The DXY dollar index is down nearly 10% YTD, and Brazil's real has strengthened over 11% against the dollar, boosting total return potential. 
While India and Indonesia have seen more stable currencies, their resilience against the greenback is still a win in the EM debt playbook.
<h2 class="wp-block-heading">Rate Cut Room &amp; Policy Stability</h2>
With inflation falling and real yields rising, central banks in emerging economies now have room to cut rates &#8211; a powerful tailwind for bond prices. 
India's CPI just hit a six-year low, Brazil is inching toward its inflation target, and Indonesia remains firmly within its policy range. 
That's in stark contrast to the U.S., where the Fed remains caught between stickier core inflation and concerns over fiscal slippage.
<h2 class="wp-block-heading">How To Play It</h2>
For investors looking to diversify income streams and hedge against dollar volatility:
<ul class="wp-block-list">
<li>LEMB: Up 9.88% YTD, offers broad exposure to sovereign debt in local currency.</li>
<li>EMLC: Up 7.43% YTD, tracks J.P. Morgan's benchmark for EM local debt.</li>
</ul>
These funds also benefit from exposure to stronger currencies and improving macro fundamentals.
U.S. Treasuries may still be the default play for safety, but in 2025, the risk-adjusted returns are flowing toward emerging markets. 
With inflation falling, currencies stabilizing, and yields sky-high, EM debt isn&#8217;t just an alternative anymore &#8211; it might just be the new safe haven.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/46014647/wall-street-watches-as-money-flows-out-of-us-markets-is-the-great-rotation-here">Wall Street Watches As Money Flows Out Of US Markets — Is The &#8216;Great Rotation&#8217; Here?</a></li>
</ul>
Image: Shutterstock

Bonds

Emerging Markets

Markets

EBND

Market Vectors Emerging Markets Local Currency Bond ETF

EMLC

LEMB

iShares Trust Barclays 20+ Year Treasury Bond Fund

Bond Bulls Look To Brazil, India, Indonesia As Emerging Market Debt Rallies

Ratings for CytoSorbents (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSO#NASDAQ">CTSO</a>) were provided by 6 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for CytoSorbents, revealing an average target of $7.0, a high estimate of $10.00, and a low estimate of $1.00. Consistency is reflected as the current average remains at the same level as the previous average price target. 
<img src="https://www.benzinga.com/files/images/story/2025/1750856413_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A comprehensive examination of how financial experts perceive CytoSorbents is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jason Kolbert</td>
<td>D. Boral Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Jason Kolbert</td>
<td>D. Boral Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Sean Lee</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$1.00</td>
<td>$1.00</td>
</tr>
<tr>
<td>Jason Kolbert</td>
<td>D. Boral Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Sean Lee</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$1.00</td>
<td>$1.00</td>
</tr>
<tr>
<td>Jason Kolbert</td>
<td>D. Boral Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to CytoSorbents. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of CytoSorbents compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of CytoSorbents's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of CytoSorbents's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/CTSO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on CytoSorbents analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>About CytoSorbents</h2>
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.
<h3>Financial Insights: CytoSorbents</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Decline in Revenue: Over the 3M period, CytoSorbents faced challenges, resulting in a decline of approximately -2.92% in revenue growth as of 31 March, 2025. This signifies a reduction in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: CytoSorbents's net margin is impressive, surpassing industry averages. With a net margin of -16.94%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): CytoSorbents's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -11.53%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): CytoSorbents's ROA stands out, surpassing industry averages. With an impressive ROA of -3.01%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: CytoSorbents's debt-to-equity ratio surpasses industry norms, standing at 1.85. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Basics of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CTSO

Deep Dive Into CytoSorbents Stock: Analyst Perspectives (6 Ratings)

SONM

Sonim Technologies shares are trading higher after the company announced it signed a non-binding Letter of Intent for a proposed reverse take-over with a private US-based company building out Nvidia-based High-Performance Computing AI factories.

Press Releases

Dolphin to Host First Quarter 2025 Earnings Call on May 13 at 4:30 PM ET

Dolphin Subsidiary The Digital Dept. Sees Surge In Affiliate Marketing Division, Driving Over $6.6 Million In Gross Retail Sales In First Quarter

Earnings

Dolphin Reports Q1 2025 Results; Core Entertainment Publicity and Marketing Segment (EPM) Revenue Up 2% YoY to $12.1 Million, Strategic Investments and New Division Launch to Drive Long-Term Growth

Dolphin Subsidiary Special Projects Curates Star-Studded Guest List for the Tory Burch Store Opening on Rodeo Drive

Shore Fire Media Clients Shape the Summer 2025 Season With Star-Studded Music Festivals and Concert Series

Dolphin to Present at Maxim Group's 2025 Virtual Tech Conference

Dolphin Subsidiary Special Projects Partners with The Peabody Awards on 2025 Awards Ceremony

Dolphin Subsidiaries Shore Fire Media and The Digital Dept. Take Over CMA Fest 2025

Dolphin Subsidiary 42West Makes Impact at 2025 Tribeca Festival with Exciting Film, TV, and Filmmaker Slate

Dolphin Subsidiaries and Clients Have Successful Showing at Cannes Lions Festival of Creativity 2025

DLPN

Anghami

BloomZ

Brera Holdings PLC - Class B Ordinary Shares

Brera Holdings

Cineverse

Pop Culture Group Co., Ltd - Class A Ordinary Shares

Pop Culture Gr

Global Mofy AI Limited - Class A Ordinary Shares

Global Mofy AI

Kuke Music Holding Limited American Depositary Shares (each representing ten (10) Class A Ordinary Shares)

Kuke Music Hldg

LiveOne

Moving iMage Technologies, Inc. Common Stock

Moving iMage Technologies

Mega Matrix

PodcastOne

Reading International Inc - Class A Non-voting Common Stock

Reading Intl

Scienjoy Holding Corporation - Class A Ordinary Shares

Scienjoy Holding

Sound Group Inc. - American Depositary Shares

Comments

Dolphin Entertainment

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL